Associations - EGFR G719X

EGFR G719X EGFR G719X	Non Small Cell Lung Cancer NSCLC	EGFR G719X EGFR G719X	Non Small Cell Lung Cancer NSCLC	afatinib Sensitive: B - Late Trials	afatinib Sensitive: B - Late Trials
EGFR G719X EGFR G719X	Non Small Cell Lung Cancer NSCLC	EGFR G719X EGFR G719X	Non Small Cell Lung Cancer NSCLC	osimertinib Sensitive: C2 – Inclusion Criteria	osimertinib Sensitive: C2 – Inclusion Criteria
EGFR G719X EGFR G719X	Non Small Cell Lung Cancer NSCLC	EGFR G719X EGFR G719X	Non Small Cell Lung Cancer NSCLC	erlotinib Sensitive: C2 – Inclusion Criteria	erlotinib Sensitive: C2 – Inclusion Criteria
EGFR G719X EGFR G719X	Non Small Cell Lung Cancer NSCLC	EGFR G719X EGFR G719X	Non Small Cell Lung Cancer NSCLC	gefitinib Sensitive: C2 – Inclusion Criteria	gefitinib Sensitive: C2 – Inclusion Criteria
EGFR G719X EGFR G719X	Lung Adenocarcinoma LUAD	EGFR G719X EGFR G719X	Lung Adenocarcinoma LUAD	afatinib Sensitive: C3 – Early Trials	afatinib Sensitive: C3 – Early Trials
EGFR G719X EGFR G719X	Non Small Cell Lung Cancer NSCLC	EGFR G719X EGFR G719X	Non Small Cell Lung Cancer NSCLC	EGFR inhibitor Sensitive: C3 – Early Trials	EGFR inhibitor Sensitive: C3 – Early Trials
EGFR G719X EGFR G719X	Non Small Cell Lung Cancer NSCLC	EGFR G719X EGFR G719X	Non Small Cell Lung Cancer NSCLC	Tyrosine kinase inhibitor Resistant: C3 – Early Trials	Tyrosine kinase inhibitor Resistant: C3 – Early Trials
EGFR G719X EGFR G719X	Lung Cancer Lung Cancer	EGFR G719X EGFR G719X	Lung Cancer Lung Cancer	pan-ErbB inhibitor Sensitive: D – Preclinical	pan-ErbB inhibitor Sensitive: D – Preclinical